Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 4Not yet recruiting 2Completed 2Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 4Head & Neck 2Gynecologic 2Genitourinary 1

Conditions

Uterine Cervical Neoplasms 2

Interventions

Paclitaxel 24Carboplatin 18Bevacizumab 14Cisplatin 12pembrolizumab 7fluzoparib 7Drug Therapy 7Radiotherapy 6camrelizumab 5apatinib 5Topotecan 5Magnetic Resonance Spectroscopy 5Injections 5liposomal doxorubicin 4lenvatinib 4famitinib 4Tirzepatide 4Specimen Handling 4Platinum 4Observation 4Gemcitabine 4Brachytherapy 4toripalimab 3olaparib 3dostarlimab 3anlotinib 3Watchful Waiting 3Therapeutics 3Surveys and Questionnaires 3Neoadjuvant Therapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × nimotuzumab × Gynecologic × Clear all
NCT06333821 2024-03-27

A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma

Biotech Pharmaceutical Co., Ltd.

Phase 3 Not yet recruiting
460 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT06039891 2023-09-15

Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer

Peking Union Medical College Hospital

Phase 2 Not yet recruiting
55 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡